Please use this identifier to cite or link to this item:
|Title:||Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment.|
|Authors:||Cheng, L;Doecke, James D;Sharples, R A;Villemagne, Victor L;Fowler, Christopher J;Rembach, Alan;Martins, Ralph N;Rowe, Christopher C;Macaulay, S Lance;Masters, Colin L;Hill, A F|
|Affiliation:||1] CSIRO Digital Productivity Flagship/The Australian E-Health Research Centre, Herston, QLD, Australia  CSIRO Food and Nutrition Flagship, Melbourne, VIC, Australia.|
1] Department of Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, VIC, Australia  Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, Australia.
1] Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia  Department of Medicine, Austin Health, Melbourne, VIC, Australia  Florey Institute, Melbourne, VIC, Australia.
Faculty of Computing Health and Science, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
1] Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia  Department of Medicine, Austin Health, Melbourne, VIC, Australia.
CSIRO Food and Nutrition Flagship, Melbourne, VIC, Australia.
Florey Institute, Melbourne, VIC, Australia.
|Citation:||Molecular Psychiatry 2014; 20(10): 1188-96|
|Abstract:||There is no consensus for a blood-based test for the early diagnosis of Alzheimer's disease (AD). Expression profiling of small non-coding RNA's, microRNA (miRNA), has revealed diagnostic potential in human diseases. Circulating miRNA are found in small vesicles known as exosomes within biological fluids such as human serum. The aim of this work was to determine a set of differential exosomal miRNA biomarkers between healthy and AD patients, which may aid in diagnosis. Using next-generation deep sequencing, we profiled exosomal miRNA from serum (N=49) collected from the Australian Imaging, Biomarkers and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR; N=60), with predictions performed using the Random Forest method. Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical and cognitive assessments, and amyloid neuroimaging with positron emission tomography were assessed. An AD-specific 16-miRNA signature was selected and adding established risk factors including age, sex and apolipoprotein ɛ4 (APOE ɛ4) allele status to the panel of deregulated miRNA resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD. Furthermore, amyloid neuroimaging information for those healthy control subjects incorrectly classified with AD-suggested progression in these participants towards AD. These data suggest that an exosomal miRNA signature may have potential to be developed as a suitable peripheral screening tool for AD.Molecular Psychiatry advance online publication, 28 October 2014; doi:10.1038/mp.2014.127.|
|Internal ID Number:||25349172|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.